Kallikrein-related peptidases: Proteolysis and signaling in cancer, the new frontier

Biological Chemistry

Volumn 391, Issue 4, 2010, Pages 299-310

  Oikonomopoulou, Katerina ^a,b,d   Diamandis, Eleftherios P ^b,c   Hollenberg, Morley D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hormone; Inflammation; Kallikrein related peptidases; Proteases; Proteinase activated receptors; Proteinases; Signaling; Trypsin

Indexed keywords

CALCIUM ION; KALLIKREIN; KALLIKREIN 13; KALLIKREIN 5; KALLIKREIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPSIN; PEPTIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TRYPSIN;

CARCINOGENESIS; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SKIN DISEASE;

ANIMALS; HORMONES; HUMANS; INFLAMMATION; KALLIKREINS; NEOPLASMS; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION;

EID: 77951439498     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2010.038     Document Type: Conference Paper

References (98)

1. Allavena, P., Garlanda, C., Borrello, M.G., Sica, A., and Mantovani, A. (2008a). Pathways connecting inflammation and cancer. Curr. Opin. Genet. Dev. 18, 3-10.
2. Allavena, P., Sica, A., Solinas, G., Porta, C., and Mantovani, A. (2008b). The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66, 1-9.
3. Arcangeli, C.G., Humphrey, P.A., Smith, D.S., Harmon, T.J., Shepherd, D.L., Keetch, D.W., and Catalona, W.J. (1998). Percentage of free serum prostate-specific antigen as a predictor of pathological features of prostate cancer in a screening population. Urology 51, 558-564.
4. Barnhart, M.I. (1965). Prothrombin synthesis: an example of hepatic function. J. Histochem. Cytochem. 13, 740-751.
5. Bayliss, W.M. and Starling, E.H. (1902). The mechanism of pancreatic secretion. J. Physiol. 28, 325-353.
6. Becker, C., Noldus, J., Diamandis, E., and Lilja, H. (2001). The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit. Rev. Clin. Lab. Sci. 38, 357-399.
7. Bhoola, K.D., Figueroa, C.D., and Worthy, K. (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1-80.
8. Blaber, S.I., Ciric, B., Christophi, G.P., Bernett, M.J., Blaber, M., Rodriguez, M., and Scarisbrick, I.A. (2004). Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J. 18, 920-922.
9. Borgoño, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
10. Borgoño, C.A., Grass, L., Soosaipillai, A., Yousef, G.M., Petraki, C.D., Howarth, D.H., Fracchioli, S., Katsaros, D., and Diamandis, E.P. (2003). Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res. 63, 9032-9041. (Pubitemid 38064085)
11. Borgoño, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257-280.
12. Borgoño, C.A., Michael, I.P., Komatsu, N., Jayakumar, A., Kapadia, R., Clayman, G.L., Sotiropoulou, G., and Diamandis, E.P. (2007a). A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 282, 3640-3652.
13. Borgoño, C.A., Michael, I.P., Shaw, J.L., Luo, L.Y., Ghosh, M.C., Soosaipillai, A., Grass, L., Katsaros, D., and Diamandis, E.P. (2007b). Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J. Biol. Chem. 282, 2405-2422.
14. Brattsand, M. and Egelrud, T. (1999). Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J. Biol. Chem. 274, 30033-30040.
15. Brattsand, M., Stefansson, K., Lundh, C., Haasum, Y., and Egelrud, T. (2005). A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 124, 198-203.
16. Briot, A., Deraison, C., Lacroix, M., Bonnart, C., Robin, A., Besson, C., Dubus, P., and Hovnanian, A. (2009). Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J. Exp. Med. 206, 1135-1147.
17. Burger, M.M. (1970). Proteolytic enzymes initiating cell division and escape from contact inhibition of growth. Nature 227, 170-171.
18. Camerer, E. (2007). Protease signaling in tumor progression. Thromb. Res. 120, S75-S81.
19. Carter, H.B., Partin, A.W., Luderer, A.A., Metter, E.J., Landis, P., Chan, D.W., Fozard, J.L., and Pearson, J.D. (1997). Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49, 379-384.
20. Catalona, W.J., Partin, A.W., Slawin, K.M., Brawer, M.K., Flanigan, R.C., Patel, A., Richie, J.P., deKernion, J.B., Walsh, P.C., Scardino, P.T., et al. (1998). Use of the percentage of free prostatespecific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J. Am. Med. Assoc. 279, 1542-1547.
21. Caubet, C., Jonca, N., Brattsand, M., Guerrin, M., Bernard, D., Schmidt, R., Egelrud, T., Simon, M., and Serre, G. (2004). Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/ hK7. J. Invest. Dermatol. 122, 1235-1244.
22. Cenac, N., Coelho, A.M., Nguyen, C., Compton, S., Andrade-Gordon, P., MacNaughton, W.K., Wallace, J.L., Hollenberg, M.D., Bunnett, N.W., Garcia-Villar, R., et al. (2002). Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am. J. Pathol. 161, 1903-1915.
23. Chavanas, S., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A.D., Bonafé, J.L., Wilkinson, J., Täeb, A., Barrandon, Y., et al. (2000). Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 25, 141-142.
24. Chen, L.B. and Buchanan, J.M. (1975). Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc. Natl. Acad. Sci. USA 72, 131-135.
25. Choong, P.F. and Nadesapillai, A.P. (2003). Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin. Orthop. Relat. Res. 415, S46-S58.
26. Coughlin, S.R. (2005). Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3, 1800-1814.
27. Coussens, L.M. and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867.
28. de Garavilla, L., Vergnolle, N., Young, S.H., Ennes, H., Steinhoff, M., Ossovskaya, V.S., D'Andrea, M.R., Mayer, E.A., Wallace, J.L., Hollenberg, M.D., et al. (2001). Agonists of proteinaseactivated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br. J. Pharmacol. 133, 975-987.
29. Deraison, C., Bonnart, C., Lopez, F., Besson, C., Robinson, R., Jayakumar, A., Wagberg, F., Brattsand, M., Hachem, J.P., Leonardsson, G., et al. (2007). LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell 18, 3607-3619.
30. Diamandis, E.P., Yousef, G.M., Petraki, C., and Soosaipillai, A.R. (2000). Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin. Biochem. 33, 663-667.
31. Fonović, M., Verhelst, S.H., Sorum, M.T., and Bogyo, M. (2007). Proteomics evaluation of chemically cleavable activity-based probes. Mol. Cell. Proteomics 6, 1761-1770.
32. Hansson, L., Strömqvist, M., Bäckman, A.,Wallbrandt, P., Carlstein, A., and Egelrud, T. (1994). Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J. Biol. Chem. 269, 19420-19426.
33. Hawthorne, S., Hamilton, R., Walker, B.J., and Walker, B. (2004). Utilization of biotinylated diphenyl phosphonates for disclosure of serine proteases. Anal. Biochem. 326, 273-275.
34. Henderson, J. (2005). Ernest Starling and 'hormones': an historical commentary. J. Endocrinol. 184, 5-10.
35. Heuzé-Vourc'h, N., Planque, C., Guyetant, S., Coco, C., Brillet, B., Blechet, C., Parent, C., Laurent, B., Reverdiau, P., Jourdan, M.L., et al. (2009). High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumor proliferation and poor prognosis. J. Cell. Mol. Med., in press. DOI: 10.1111/ j.1582-4934.2009.00763.x.
36. Hollenberg, M.D. and Compton, S.J. (2002). International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol. Rev. 54, 203-217.
37. Houle, S., Papez, M.D., Ferazzini, M., Hollenberg, M.D., and Vergnolle, N. (2005) Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br. J. Pharmacol. 146, 670-678.
38. Iwata, A., Maruyama, M., Akagi, T., Hashikawa, T., Kanazawa, I., Tsuji, S., and Nukina, N. (2003). a-Synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum. Mol. Genet. 12, 2625-2635.
39. Klokk, T.I., Kilander, A., Xi, Z., Waehre, H., Risberg, B., Danielsen, H.E., and Saatcioglu, F. (2007). Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res. 67, 5221-5230.
40. Klucky, B., Mueller, R., Vogt, I., Teurich, S., Hartenstein, B., Breuhahn, K., Flechtenmacher, C., Angel, P., and Hess, J. (2007). Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res. 67, 8198-8206.
41. Komatsu, N., Saijoh, K., Sidiropoulos, M., Tsai, B., Levesque, M.A., Elliott, M.B., Takehara, K., and Diamandis, E.P. (2005). Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. J. Invest. Dermatol. 125, 1182-1189.
42. Komatsu, N., Tsai, B., Sidiropoulos, M., Saijoh, K., Levesque, M.A., Takehara, K., and Diamandis, E.P. (2006). Quantification of eight tissue kallikreins in the stratum corneum and sweat. J. Invest. Dermatol. 126, 925-929.
43. Komatsu, N., Saijoh, K., Jayakumar, A., Clayman, G.L., Tohyama, M., Suga, Y., Mizuno, Y., Tsukamoto, K., Taniuchi, K., Takehara, K., et al. (2008). Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J. Invest. Dermatol. 128, 1148-1159.
44. Kono, T. and Barham, F.W. (1971). Insulin-like effects of trypsin on fat cells. Localization of the metabolic steps and the cellular site affected by the enzyme. J. Biol. Chem. 246, 6204-6209.
45. Law, R.H., Zhang, Q., McGowan, S., Buckle, A.M., Silverman, G.A., Wong, W., Rosado, C.J., Langendorf, C.G., Pike, R.N., Bird, P.I., et al. (2006). An overview of the serpin superfamily. Genome Biol. 7, 216.
46. Little, S.P., Dixon, E.P., Norris, F., Buckley, W., Becker, G.W., Johnson, M., Dobbins, J.R., Wyrick, T., Miller, J.R., MacKellar, W., et al. (1997). Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J. Biol. Chem. 272, 25135-25142.
47. Loeb, S. and Catalona, W.J. (2007). Prostate-specific antigen in clinical practice. Cancer Lett. 249, 30-39.
48. López-Ot́n, C. and Matrisian, L.M. (2007). Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800-808.
49. Luo, W., Wang, Y., and Reiser, G. (2007). Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res. Rev. 56, 331-345.
50. Macarthur, M., Hold, G.L., and El-Omar, E.M. (2004). Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G515-G520.
51. Macfarlane, S.R., Seatter, M.J., Kanke, T., Hunter, G.D., and Plevin, R. (2001). Proteinase-activated receptors. Pharmacol. Rev. 53, 245-282.
52. Mitsui, S., Okui, A., Uemura, H., Mizuno, T., Yamada, T., Yamamura, Y., and Yamaguchi, N. (2002). Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease. Ann. N.Y. Acad. Sci. 977, 216-223.
53. Mize, G.J., Wang, W., and Takayama, T.K. (2008). Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mol. Cancer Res. 6, 1043-1051.
54. Molino, M., Barnathan, E.S., Numerof, R., Clark, J., Dreyer, M., Cumashi, A., Hoxie, J.A., Schechter, N., Woolkalis, M., and Brass, L.F. (1997a). Interactions of mast cell tryptase with thrombin receptors and PAR-2. J. Biol. Chem. 272, 4043-4049.
55. Molino, M., Woolkalis, M.J., Reavey-Cantwell, J., Pratico, D., Andrade-Gordon, P., Barnathan, E.S., and Brass, L.F. (1997b). Endothelial cell thrombin receptors and PAR-2. Two proteaseactivated receptors located in a single cellular environment. J. Biol. Chem. 272, 11133-11141.
56. Nguyen, C., Coelho, A.M., Grady, E., Compton, S.J., Wallace, J.L., Hollenberg, M.D., Cenac, N., Garcia-Villar, R., Bueno, L., Steinhoff, M., et al. (2003). Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Can. J. Physiol. Pharmacol. 81, 920-927.
57. Noorbakhsh, F., Tsutsui, S., Vergnolle, N., Boven, L.A., Shariat, N., Vodjgani, M., Warren, K.G., Andrade-Gordon, P., Hollenberg, M.D., and Power, C. (2006). Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 203, 425-435.
58. Obiezu, C.V. and Diamandis, E.P. (2005). Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 224, 1-22.
59. Ogawa, K., Yamada, T., Tsujioka, Y., Taguchi, J., Takahashi, M., Tsuboi, Y., Fujino, Y., Nakajima, M., Yamamoto, T., Akatsu, H., et al. (2000). Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry Clin. Neurosci. 54, 419-426.
60. Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Tea, I., Blaber, M., Blaber, S.I., Scarisbrick, I., Andrade-Gordon, P., Cottrell, G.S., Bunnett, N.W., et al. (2006a) Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem. 281, 32095-32112.
61. Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Vergnolle, N., Tea, I., Blaber, M., Blaber, S.I., Scarisbrick, I., Diamandis, E.P., and Hollenberg, M.D. (2006b). Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol. Chem. 387, 817-824.
62. Oikonomopoulou, K., Hansen, K.K., Chapman, K., Vergnolle, N., Diamandis, E.P., and Hollenberg, M.D. (2007). Kallikrein-mediated activation of PARs in inflammation and nociception. Inflamm. Res. 56, S499-S502.
63. Oikonomopoulou, K., Hansen, K.K., Baruch, A., Hollenberg, M.D., and Diamandis, E.P. (2008). Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. Biol. Chem. 389, 747-756.
64. Oikonomopoulou, K., Batruch, I., Smith, C.R., Soosaipillai, A., Diamandis, E.P., and Hollenberg, M.D. (2010). Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid. Biol. Chem. 391, 381-390.
65. Pan, Z., Jeffery, D.A., Chehade, K., Beltman, J., Clark, J.M., Grothaus, P., Bogyo, M., and Baruch, A. (2006). Development of activity-based probes for trypsin-family serine proteases. Bioorg. Med. Chem. Lett. 16, 2882-2885.
66. Paulick, M.G. and Bogyo, M. (2008). Application of activity-based probes to the study of enzymes involved in cancer progression. Curr. Opin. Genet. Dev. 18, 97-106.
67. Ramachandran, R. and Hollenberg, M.D. (2008). Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol. 153, S263-S282.
68. Ramsay, A.J., Dong, Y., Hunt, M.L., Linn, M., Samaratunga, H., Clements, J.A., and Hooper, J.D. (2008a). Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J. Biol. Chem. 283, 12293-12304.
69. Ramsay, A.J., Reid, J.C., Adams, M.N., Samaratunga, H., Dong, Y., Clements, J.A., and Hooper, J.D. (2008b). Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostateexpressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biol. Chem. 389, 653-668.
70. Rieser, P. (1967). The insulin-like action of pepsin and pepsinogen. Acta Endocrinol. (Copenh.) 54, 375-379.
71. Rieser, P. and Rieser, C.H. (1964). Anabolic responses of diaphragm muscle to insulin and to other pancreatic proteins. Proc. Soc. Exp. Biol. Med. 116, 669-671.
72. Roberts, R.A. and Gullick, W.J. (1989). Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene. J. Cell Sci. 94, 527-535.
73. Rogers, A.B. and Fox, J.G. (2004). Inflammation and Cancer. I. Rodent models of infectious gastrointestinal and liver cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G361-G366.
74. Sadaghiani, A.M., Verhelst, S.H., and Bogyo, M. (2007). Tagging and detection strategies for activity-based proteomics. Curr. Opin. Chem. Biol. 11, 20-28.
75. Scarisbrick, I.A., Blaber, S.I., Lucchinetti, C.F., Genain, C.P., Blaber, M., and Rodriguez, M. (2002). Activity of a newly identified serine protease in CNS demyelination. Brain 125, 1283-1296.
76. Scarisbrick, I.A., Blaber, S.I., Tingling, J.T., Rodriguez, M., Blaber, M., and Christophi, G.P. (2006). Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J. Neuroimmunol. 178, 167-176.
77. Scarisbrick, I.A., Linbo, R., Vandell, A.G., Keegan, M., Blaber, S.I., Blaber, M., Sneve, D., Lucchinetti, C.F., Rodriguez, M., and Diamandis, E.P. (2008). Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol. Chem. 389, 739-745.
78. Schmaier, A.H. and McCrae, K.R. (2007). The plasma kallikreinkinin system: its evolution from contact activation. J. Thromb. Haemost. 5, 2323-2329.
79. Sefton, B.M. and Rubin, H. (1970). Release from density dependent growth inhibition by proteolytic enzymes. Nature 227, 843-845.
80. Seiki, M. (2003). Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 194, 1-11.
81. Shimizu, C., Yoshida, S., Shibata, M., Kato, K., Momota, Y., Matsumoto, K., Shiosaka, T., Midorikawa, R., Kamachi, T., Kawabe, A., et al. (1998). Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J. Biol. Chem. 273, 11189-11196.
82. Shoelson, S.E., White, M.F., and Kahn, C.R. (1988). Tryptic activation of the insulin receptor. Proteolytic truncation of the asubunit releases the b-subunit from inhibitory control. J. Biol. Chem. 263, 4852-4860.
83. Sotiropoulou, G., Pampalakis, G., and Diamandis, E.P. (2009). Functional role of human kallikrein-related peptidases. J. Biol. Chem. 284, 32989-32994.
84. Stack, M.S., Ellerbroek, S.M., and Fishman, D.A. (1998). The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int. J. Oncol. 12, 569-576.
85. Stefansson, K., Brattsand, M., Ny, A., Glas, B., and Egelrud, T. (2006). Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum. Biol. Chem. 387, 761-768.
86. Stefansson, K., Brattsand, M., Roosterman, D., Kempkes, C., Bocheva, G., Steinhoff, M., and Egelrud, T. (2008). Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J. Invest. Dermatol. 128, 18-25.
87. Steinhoff, M., Buddenkotte, J., Shpacovitch, V., Rattenholl, A., Moormann, C., Vergnolle, N., Luger, T.A., and Hollenberg, M.D. (2005). Proteinase-activated receptors: transducers of proteinasemediated signaling in inflammation and immune response. Endocr. Rev. 26, 1-43.
88. Steinhoff, M., Vergnolle, N., Young, S.H., Tognetto, M., Amadesi, S., Ennes, H.S., Trevisani, M., Hollenberg, M.D., Wallace, J.L., Caughey, G.H., et al. (2000). Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat. Med. 6, 151-158.
89. Tamura, H., Ishikawa, Y., Hino, N., Maeda, M., Yoshida, S., Kaku, S., and Shiosaka, S. (2006). Neuropsin is essential for early processes of memory acquisition and Schaffer collateral long-term potentiation in adult mouse hippocampus in vivo. J. Physiol. 570, 541-551.
90. Terayama, R., Bando, Y., Murakami, K., Kato, K., Kishibe, M., and Yoshida, S. (2007). Neuropsin promotes oligodendrocyte death, demyelination and axonal degeneration after spinal cord injury. Neuroscience 148, 175-187.
91. Vandell, A.G., Larson, N., Laxmikanthan, G., Panos, M., Blaber, S.I., Blaber, M., and Scarisbrick, I.A. (2008). Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines. J. Neurochem. 107, 855-870.
92. Vergnolle, N. (2004). Modulation of visceral pain and inflammation by protease-activated receptors. Br. J. Pharmacol. 141, 1264-1274.
93. Vergnolle, N., Hollenberg, M.D., Sharkey, K.A., and Wallace, J.L. (1999). Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br. J. Pharmacol. 127, 1083-1090.
94. Vergnolle, N., Bunnett, N.W., Sharkey, K.A., Brussee, V., Compton, S.J., Grady, E.F., Cirino, G., Gerard, N., Basbaum, A.I., Andrade-Gordon, P., et al. (2001a). Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat. Med. 7, 821-826.
95. Vergnolle, N., Wallace, J.L., Bunnett, N.W., and Hollenberg, M.D. (2001b). Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol. Sci. 22, 146-152.
96. Wang, W., Mize, G.J., Zhang, X., and Takayama, T.K. (2010). Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1. Int. J. Cancer 126, 599-610.
97. Yousef, G.M., Kishi, T., and Diamandis, E.P. (2003). Role of kallikrein enzymes in the central nervous system. Clin. Chim. Acta 329, 1-8.
98. Zarghooni, M., Soosaipillai, A., Grass, L., Scorilas, A., Mirazimi, N., and Diamandis, E.P. (2002). Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin. Biochem. 35, 225-231.